AMAG Pharmaceuticals (AMAG) Offers Q4 Sales Guidance Below Expectations
Tweet
Share
E-mailGet Alerts AMAG Hot Sheet
Price: $13.75 --0%
Financial Fact:
Research and development expenses: 17.12M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Research and development expenses: 17.12M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced a business update, including preliminary fourth quarter 2011 financial results and its outlook for 2012. The company will present further details at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2012 at 3:00 p.m. Pacific time.
AMAG expects to report fourth quarter 2011 total revenues of between $14.3 and $15.0 million, versus the consensus of$16.11 million including between $12.4 and $13.1 million in net Feraheme product revenues. Total operating costs and expenses are expected to be between $38 and $43 million, including certain restructuring costs and a $2 million termination fee paid to Allos Therapeutics.
The company is committed to managing the business to achieve cash flow breakeven in 2012 and is reiterating the guidance provided when the company announced the November 2011 restructuring.
AMAG hired Jefferies & Company, Inc. as a strategic advisor. Jefferies is assisting the company in identifying and evaluating various strategies to enhance stockholder value and leverage AMAG’s core assets – Feraheme, AMAG’s commercial and drug development infrastructure, and the company’s balance sheet, which had more than $225 million in cash and investments, and no debt, as of December 31, 2011.
AMAG expects to report fourth quarter 2011 total revenues of between $14.3 and $15.0 million, versus the consensus of$16.11 million including between $12.4 and $13.1 million in net Feraheme product revenues. Total operating costs and expenses are expected to be between $38 and $43 million, including certain restructuring costs and a $2 million termination fee paid to Allos Therapeutics.
The company is committed to managing the business to achieve cash flow breakeven in 2012 and is reiterating the guidance provided when the company announced the November 2011 restructuring.
AMAG hired Jefferies & Company, Inc. as a strategic advisor. Jefferies is assisting the company in identifying and evaluating various strategies to enhance stockholder value and leverage AMAG’s core assets – Feraheme, AMAG’s commercial and drug development infrastructure, and the company’s balance sheet, which had more than $225 million in cash and investments, and no debt, as of December 31, 2011.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Etsy upgraded to buy at BofA on durable growth, buyback potential
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
- Walmart shares fall despite earnings beat
Create E-mail Alert Related Categories
GuidanceRelated Entities
JPMorgan, Jefferies & Co, Earnings, AMAG Pharma/Allos TherapeuticsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
